Late stage prostate cancer (CAP) tumors are resistant to anticancer therapies that cause cell death through the induction of apoptosis. To understand how CaP cells become resistant to apoptotic stimuli, it is important to characterize the molecular pathways that control apoptosis. This proposal focuses on the requirement of the transcription factor NF-kappaB for cell survival in CaP cells in response to interleukin-1 (IL-1)beta-dependent Ca 2+ signaling and apoptosis. Preliminary data presented in this proposal demonstrates that IL-1beta-induced NF-kappaB activity will overcome growth factor induced apoptosis in CaP cells. However, IL-1beta will also induce apoptosis in CaP cells through a Ca2+ -dependent pathway, following the inactivation of NF-kappaB. These results suggest that NF-kappaB activity is required to maintain Ca 2+ homeostasis in CaP cells following IL-1beta stimulation. This is supported by the fact that IL-1beta activates NF-kappaB, in part, through Ca2+/calmodulin-dependent kinases (CaMKs), namely CaMKK and CaMKIV. IL-1beta-induced NF-kappaB activity is required to upregulate transcripts encoding Ca2+-binding proteins (CaBP), including calreticulin, calbindin-3, and DSCR1. Expression of calreticulin blocked Ca 2+ -induced apoptosis in our model system. The overall hypothesis of this proposal is that IL-1beta-induced NF-kappaB activity is required to upregulate gene products that feedback to regulate Ca 2+ levels and modulate apoptosis in CaP cells. To address this hypothesis, the following aims will be explored.
Aim 1 will establish whether CaP patients display, elevated IL-1beta. Experiments' proposed in Aim 1 will also identify whether intracellular release of Ca2+ is responsible for inducing apoptosis, and will determine if this effect impacts cytochrome c release, caspase and/or calpain activation, and subsequent cleavage of CaMK and IkappaB/NF-kappaB substrates.
Aim 2 will identify the CaMK signaling pathways responsible for upregulating NF-kappaB transcriptional activity and cell survival. Experiments outlined in Aim 2 will use dominant negative and constitutively active kinases to identify CaMK pathways required to activate NF-kappaB in response to IL-1beta, and will determine the impact of these signaling pathways on the transactivation potential of NF-kappaB.
Aim 3 will elucidate whether the calreticulin promoter is a direct target of NF-kappaB and determine if the expression of calreticulin alone or in combination with other NF-kappaB-regulated CaBPs rescues apoptosis. Experiments described in Aim 3 will determine whether NF-kappaB directly upregulates the calreticulin promoter, and will potentially identify regulated Ca2+ -binding proteins. Additional experiments proposed in Aim 3 will determine whether the expression of these proteins alone or in combination with calreticulin will rescue Ca2+ -induced apoptosis. Collectively, the experiments outlined in this proposal will offer insight into the anti-apoptotic role of NF-kappaB in Ca 2+ signaling in CaP cells, and will potentially provide a better understanding of how NF-kappaB overcomes Ca2+ -induced apoptotic cues initiatcd by growth factors and cytokines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA095644-01A1
Application #
6572912
Study Section
Pathology B Study Section (PTHB)
Program Officer
Perry, Mary Ellen
Project Start
2003-01-01
Project End
2007-12-31
Budget Start
2003-01-01
Budget End
2003-12-31
Support Year
1
Fiscal Year
2003
Total Cost
$306,706
Indirect Cost
Name
University of Virginia
Department
Biochemistry
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Ramsey, C S; Yeung, F; Stoddard, P B et al. (2008) Copine-I represses NF-kappaB transcription by endoproteolysis of p65. Oncogene 27:3516-26
Wang, Jialiang; An, Hanbing; Mayo, Marty W et al. (2007) LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell 12:239-51
Hoberg, Jamie E; Popko, Anita E; Ramsey, Catherine S et al. (2006) IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300. Mol Cell Biol 26:457-71
Burstein, Ezra; Hoberg, Jamie E; Wilkinson, Amanda S et al. (2005) COMMD proteins, a novel family of structural and functional homologs of MURR1. J Biol Chem 280:22222-32
Yeung, Fan; Hoberg, Jamie E; Ramsey, Catherine S et al. (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23:2369-80
Denlinger, Chadrick E; Keller, Michael D; Mayo, Marty W et al. (2004) Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg 127:1078-86
Hoberg, Jamie E; Yeung, Fan; Mayo, Marty W (2004) SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival. Mol Cell 16:245-55
Mayo, Marty W; Denlinger, Chadrick E; Broad, Robert M et al. (2003) Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J Biol Chem 278:18980-9